TNXP

Tonix Pharmaceuticals Holding Corp. | Cotação de Ações

Última atualização31/01/2025, 18:00:01

PreçoUS$ 0,43

Variação (dia)US$ 0,05 (14.13%)▲

Min. 52 SemanasUS$ 0,12

Máx. 52 SemanasUS$ 12,48

Capitalização de mercado--

Endereço: 26 Main Street, Chatham, NJ, 07928

Telefone: 862 799 8599

Funcionários: 103

Tonix Pharmaceuticals Holding CTNXP

US$ 0,43

+ 0,05314%

31/01/2025 18:00:01

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualUS$ 0,43

Valor de mercado--

AberturaUS$ 0,42

Preço máximoUS$ 0,45

Preço mínimoUS$ 0,40

VolumeUS$ 70 mi

Fechamento anteriorUS$ 0,38

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Ações relacionadas

IBIO,JAGX,ZOM,OCGN,VXRT

IBIO,JAGX,ZOM,OCGN,VXRT ▼0.00% | R$ 0,00

Fique por dentro das últimas notícias do mundo financeiro em nosso Blog

Mantenha-se atualizado com as últimas notícias financeiras em nosso Blog. Publicamos artigos informativos e análises de especialistas para fornecer insights valiosos sobre o cenário financeiro em constante evolução.

Busque ativos específicos e obtenha informações detalhadas sobre suas cotações

Utilize a função de busca para encontrar informações detalhadas sobre ativos específicos. Oferecemos dados precisos e atualizados, permitindo que você tome decisões informadas com base nas informações mais recentes do mercado.

Assine nossa newsletter para receber atualizações gratuitas por e-mail

Mantenha-se informado assinando nossa newsletter. Receba atualizações gratuitas por e-mail, incluindo rendimentos, novidades do mercado e insights valiosos. Estamos comprometidos em fornecer informações relevantes diretamente à sua caixa de entrada.